Cerapedics receives FDA approval for i-FACTOR Peptide Enhanced Bone Graft in Cervical Spine Surgery
Orthobiologics company positioned to begin commercial distribution in the U.S. following successful Premarket Approval application
Find out moreCerapedics announces FDA Advisory Committee Panel Is not required for i-FACTOR PMA Approval
Orthobiologics company has submitted response to remaining items from PMA review of i-FACTOR Peptide Enhanced Bone Graft
Find out moreCerapedics announces closing of loan and equity financing
Cerapedics, a privately-held orthobiologics company, today announced closing of a $4 million term loan from GE Capital, Healthcare Financial Services, bringing the total facility to $16.5 million. The company also a…
Find out moreStudy supports use of Cerapedics i-FACTOR Biologic Bone Graft as alternative to Autograft in common spine surgery for chronic back pain
Results published in International Journal of Spine Surgery
Find out moreCerapedics receives CE mark and TGA listing for new i-FACTOR™ Flex FR Biologic Bone Graft
Proven P-15 bone graft technology now features enhanced handling with addition of purified silk fibers
Find out moreNovel i-FACTOR Biologic Bone Graft Shown to improve clinical outcomes in ALIF procedures
Results from the first prospective clinical study of i-FACTOR bone graft in anterior lumbar interbody fusion surgery published in the Journal of Neurosurgery: Spine
Find out moreCerapedics files premarket approval application with US FDA for i-FACTOR™ Peptide Enhanced Bone Graft
Application is supported by data from a pivotal clinical trial demonstrating that i-FACTOR bone graft can be used as an alternative to autograft harvesting in certain procedures
Find out moreCerapedics announces closing of venture debt loan from GE Capital
Cerapedics today announced closing of a $9 million venture debt financing from GE Capital, Healthcare Financial Services.
Find out moreCerapedics announces positive results from IDE clinical trial
Results provide significant support to advance i-FACTOR™ Peptide Enhanced Bone Graft for FDA regulatory review.
Find out moreCerapedics to present preliminary outcomes data From i-FACTOR Bone Graft Study at Canaccord Genuity Musculoskeletal Conference
Cerapedics today that preliminary outcomes data from the company's FDA Investigational Device Exemption (IDE) clinical trial for i-FACTOR Peptide Enhanced Bone Graft will be presented at the Canaccord Genuity Muscul…
Find out more
Welcome to Cerapedics
Choose your region
